hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06317012, orgStudyIdInfo id: 0407-03/2022, briefTitle: Computer-Aided Design/Manufacturing for Le Fort I Osteotomy and 3D-customized Titanium Plate in Orthognathic Surgery, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-05-01, primaryCompletionDateStruct date: 2023-05-30, completionDateStruct date: 2023-06-30, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Hams Hamed Abdelrahman, class: OTHER, descriptionModule briefSummary: Background: In orthognathic surgery, virtual planning is gradually taking over in clinical practice. To start with, virtual surgery planning (VSP) is believed to be less time-consuming and less expensive than conventional surgery planning (CSP). Moreover, the improved visualization of craniofacial deformities, such as occlusal canting and asymmetries, is a further advantage. Aim: To assess the result of Le Fort I osteotomy using CAD/CAM and 3Dcustomized titanium plate with virtual planning in orthognathic surgery. Materials and Methods: 8 patients with vertical maxillary excess will be included in the study. Le Fort I osteotomy using CAD CAM surgical guide and 3Dcustomized plate will be done for the study group. All patients will be followed clinically and radiographically for one month., conditionsModule conditions: Le Fort; I, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 8, type: ACTUAL, armsInterventionsModule interventions name: Le Fort I osteotomy using CAD CAM surgical guide and 3Dcustomized plate, outcomesModule primaryOutcomes measure: Change in pain, primaryOutcomes measure: change in edema, primaryOutcomes measure: Change in post operative osteotomy position, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Alexandria Faculty of Dentistry, city: Alexandria, country: Egypt, geoPoint lat: 31.21564, lon: 29.95527, hasResults: False
protocolSection identificationModule nctId: NCT06316999, orgStudyIdInfo id: 23-012169, briefTitle: Intestinal Ultrasound for the Evaluation of Pouchitis and Other Outcomes After Ileal Pouch-Anal Anastomosis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: Intestinal ultrasound (IUS) has been studied in the evaluation of inflammatory bowel disease (IBD) and is increasingly used as a non-invasive, easy to use, cost-effective tool for point-of-care to assess disease activity and more recently to predict response to treatment. However, there is a paucity of data on the use of IUS specifically for ulcerative colitis (UC) patients with an ileal pouch-anal anastomosis (IPAA)., conditionsModule conditions: Ulcerative Colitis, conditions: Pouchitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Intestinal Ultrasound, outcomesModule primaryOutcomes measure: Diagnostic accuracy of intestinal ultrasound (IUS) for pouchitis, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Darrell Pardi, MD, MS, role: CONTACT, phone: 507-284-2511, email: pardi.darrell@mayo.edu, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06316973, orgStudyIdInfo id: CS-1103-01, secondaryIdInfos id: U01DA053054, type: NIH, link: https://reporter.nih.gov/quickSearch/U01DA053054, briefTitle: A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-07, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2024-07, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Clear Scientific, Inc., class: INDUSTRY, collaborators name: National Institute on Drug Abuse (NIDA), descriptionModule briefSummary: The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants., conditionsModule conditions: Substance Use Disorders, conditions: Methamphetamine Abuse, conditions: Methamphetamine Intoxication, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized, Double-Blind, Placebo-Controlled, Single Center Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CS-1103 Following Single, Ascending Intravenous Dose Administration in Healthy Participants, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: CS-1103, interventions name: Sterile Saline, outcomesModule primaryOutcomes measure: Number of participants with treatment-related adverse events (AEs) assessed by physical examinations, primaryOutcomes measure: Number of participants with treatment-related adverse events (AEs) assessed by vital signs, primaryOutcomes measure: Number of participants with treatment-related adverse events (AEs) assessed by electrocardiograms (ECGs), primaryOutcomes measure: Number of participants with treatment-related adverse events (AEs) assessed by laboratory parameters, secondaryOutcomes measure: Time course of CS-1103 blood and urine concentrations, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Dr. Vince Clinical Research, status: RECRUITING, city: Overland Park, state: Kansas, zip: 66212, country: United States, contacts name: Lori Adriano, role: CONTACT, phone: 913-333-3000, contacts name: Steven Hull, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 38.98223, lon: -94.67079, hasResults: False
protocolSection identificationModule nctId: NCT06316947, orgStudyIdInfo id: FMCH-2024-32723, briefTitle: Developing and Pilot Testing an Intervention to Reduce Household Shisha Smoke Exposure Within Somali Homes, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-02-01, primaryCompletionDateStruct date: 2025-10-01, completionDateStruct date: 2026-01-01, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: University of Minnesota, class: OTHER, descriptionModule briefSummary: Previous qualitative research among Somali American adults in Minnesota have identified high levels of hookah or shisha (hereafter shisha) use in Somali households. Household shisha use exposes all family members, including children, to secondhand smoke (SHS) that contains toxins that can cause many different acute and chronic disease, including increased levels of several cancers such as lung, bladder, and oral cancers. Despite the high levels of shisha use, gaps in the knowledge of the risks of shisha use and how to mitigate the potential harmful health consequences of shisha use exist among Somali Americans.This study aims to pilot test the feasibility of a newly developed CHW-delivered intervention to reduce home shisha SHS exposure with n=15 Somali families. Pre-/post-measurements of family members' (1 adult and 1 child) urine or salivary cotinine levels will be obtained along with a brief pre-/post-survey to characterize household tobacco use and the presence of home smoke-free rules., conditionsModule conditions: Shisha, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: a feasibility pilot of the new CHW-delivered intervention to reduce home shisha SHS exposure with n=15 Somali families., primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: CHW-delivered intervention, outcomesModule primaryOutcomes measure: Recruitment rate, primaryOutcomes measure: Retention rate measure, primaryOutcomes measure: pre-/post- survey completion rates, primaryOutcomes measure: pre-/post- biospecimen completion rates, secondaryOutcomes measure: shisha use changes, secondaryOutcomes measure: tobacco product use changes, secondaryOutcomes measure: smoke-free home rules, secondaryOutcomes measure: the cotinine levels of parents and children., eligibilityModule sex: ALL, minimumAge: 6 Months, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06316921, orgStudyIdInfo id: TCHIRB-11003008-E, briefTitle: Epidural PCA on Pain Relief After L-spine Surgery, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-06-01, primaryCompletionDateStruct date: 2021-12-31, completionDateStruct date: 2021-12-31, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Taipei City Hospital, class: OTHER_GOV, descriptionModule briefSummary: This study aimed to evaluate the effect of epidural patient-controlled analgesia (PCA) on postoperative pain relief after lumbar spine surgeries. The eligible patients received two types of postoperative pain management: PCA and standard pain treatment. Comparisons between the two groups were made in terms of postoperative pain level., conditionsModule conditions: Pain, Postoperative, conditions: Lumbar Spine Degeneration, conditions: Analgesia, Patient-Controlled, conditions: Epidural Anesthesia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 209, type: ACTUAL, armsInterventionsModule interventions name: Epidural patient-controlled analgesia, interventions name: Standard postoperative pain management, outcomesModule primaryOutcomes measure: Pain degree, secondaryOutcomes measure: The number of morphine injections, otherOutcomes measure: Length of hospitalization, otherOutcomes measure: Drainage amount, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Taipei City Hospital, city: Taipei, country: Taiwan, geoPoint lat: 25.04776, lon: 121.53185, hasResults: False
protocolSection identificationModule nctId: NCT06316908, orgStudyIdInfo id: ERC-2019/A187, briefTitle: Permanent Celiac Plexus Block: Comparison of Pain Score in Unilateral and Bilateral Posterior Percutaneous Approach, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-02-25, primaryCompletionDateStruct date: 2022-07-15, completionDateStruct date: 2023-03-15, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Sindh Institute of Urology and Transplantation, class: OTHER, descriptionModule briefSummary: The goal of this prospective, interventional, non-randomized study was to compare pain score in unilateral and bilateral posterior percutaneous neurolytic celiac plexus block (NCPB) in upper abdominal cancer patients.The main questions it aimed to answer are:1. Whether unilateral or bilateral NCPB technique has a better pain relief2. Was there any difference in terms of complication rates between these two approaches All participants were having upper abdominal cancer whether operated or non-operable cancer were given a unilateral or bilateral neurolytic celiac plexus block.Pain scores and adverse events at multiple time points post-procedure were recorded., conditionsModule conditions: Abdominal Cancer, conditions: Cancer Pain, conditions: Cancer of Pancreas, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Unilateral Approach Group: Patients in this group have received a unilateral percutaneous posterior approach for NCPB. The procedure was performed under fluoroscopic guidance.Bilateral Approach Group: Patients in this group have undergone a bilateral percutaneous posterior approach for NCPB, following the same procedural guidance., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ACTUAL, armsInterventionsModule interventions name: Unilateral Neurolytic Celiac Plexus Block with Absolute Alcohol, interventions name: Bilateral Neurolytic Celiac Plexus Block with Absolute Alcohol, outcomesModule primaryOutcomes measure: Pain Score using the Visual Analog Scale, secondaryOutcomes measure: Change in Mean Arterial Pressure, secondaryOutcomes measure: Incidence of Patient-Reported Nausea Feeling, secondaryOutcomes measure: Incidence of Vomiting, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sindh Institute of Urology and Transplantation, city: Karachi, state: Sindh, zip: 74200, country: Pakistan, geoPoint lat: 24.8608, lon: 67.0104, hasResults: False
protocolSection identificationModule nctId: NCT06316895, orgStudyIdInfo id: S2023-706, briefTitle: The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2027-04-01, completionDateStruct date: 2029-12-31, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Chinese PLA General Hospital, class: OTHER, descriptionModule briefSummary: 1. To evaluate the clinical outcomes of ultrasound-guided thermal ablation and thyroid surgery for the treatment of papillary thyroid carcinoma;2. To develop and validate a artificial intelligence model to predict the outcomes of ultrasound-guided thermal ablation in the treatment of papillary thyroid carcinoma;, conditionsModule conditions: Papillary Thyroid Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 3772, type: ESTIMATED, armsInterventionsModule interventions name: thyroid surgery, interventions name: ultrasound-guided thermal ablation, outcomesModule primaryOutcomes measure: rate of disease progression, secondaryOutcomes measure: Rate of complications, secondaryOutcomes measure: Rate of tumor disappearance, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06316882, orgStudyIdInfo id: ROCGAS 01, secondaryIdInfos id: ROGCAS Study, type: OTHER, domain: ULSNA, briefTitle: Opportunistic Gastric Cancer Screening, acronym: ROCGAS, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-02-03, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Unidade Local De Saúde Do Norte Alentejano, class: OTHER, collaborators name: NOVA Medical School, descriptionModule briefSummary: Endoscopic screening of gastric cancer combined with screening colonoscopy, conditionsModule conditions: Gastric Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 139, type: ESTIMATED, armsInterventionsModule interventions name: Screening endoscopy, outcomesModule primaryOutcomes measure: number of gastric adenocarcinoma, secondaryOutcomes measure: number of pre-malignant lesions, secondaryOutcomes measure: Costs of screening endoscopy, secondaryOutcomes measure: Socio-demographic characteristics of population in screening program, eligibilityModule sex: ALL, minimumAge: 40 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: ULSNA, status: RECRUITING, city: Portalegre, zip: 7300-853, country: Portugal, contacts name: Beatriz Mourato, MD, role: CONTACT, phone: 00351910311213, email: 2091@ulsna.min-saude.pt, contacts name: Beatriz Mourato, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Guilherme Santos, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Sara Morais, MD, role: SUB_INVESTIGATOR, contacts name: Nuno Pratas, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Filipa Taré, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.29379, lon: -7.43122, hasResults: False
protocolSection identificationModule nctId: NCT06316869, orgStudyIdInfo id: STVi, briefTitle: Noninvasive Prediction of Portal Hypertension in Cirrhosis Using Sound Touch Viscoelastography, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2025-03-31, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: First Affiliated Hospital of Wenzhou Medical University, class: OTHER, descriptionModule briefSummary: The objective of this observational study is to investigate and validate the utility of the Sound Touch Viscoelastography(STVi) technique in patients with liver cirrhosis for noninvasive prediction of Portal hypertension (PH). The primary research questions it seeks to address are as follows:* What is the correlation between the liver STVi index and Portal Venous Pressure Gradient (HVPG)?* Is STVi an available tool to non-invasively predict PH in patients with liver cirrhosis? And the effectiveness and practicality of STVi will be validated.* To establish a predictive model for Clinically Significant Portal Hypertension (CSPH) utilizing liver STVi index as the primary indicator.The HVPG is considered as the gold standard in our study and STVi was employed to quantify the STVi index of the liver in patients with liver cirrhosis. Researchers will compare the two patients groups, HVPG≥10 mmHg and HVPG\<10 mmHg, to see the usage of STVi in the noninvasive prediction of PH., conditionsModule conditions: Portal Hypertension, conditions: Cirrhosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 216, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: STVi index, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: the First Affiliated Hospital the First Affiliated Hospital, city: Wenzhou, state: Zhejiang, zip: 325006, country: China, geoPoint lat: 27.99942, lon: 120.66682, hasResults: False
protocolSection identificationModule nctId: NCT06316843, orgStudyIdInfo id: BHC202 v2.1, briefTitle: Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2, acronym: PASC, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-15, primaryCompletionDateStruct date: 2024-08, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Bateman Horne Center, class: OTHER, descriptionModule briefSummary: To explore the safety and efficacy of daily doses of celecoxib + valacyclovir in the treatment of patients with prolonged symptoms caused by COVID-19., conditionsModule conditions: Long COVID, conditions: PASC Post Acute Sequelae of COVID 19, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Valacyclovir celecoxib dose 1, interventions name: Valacyclovir celecoxib dose 2, interventions name: Placebo, outcomesModule primaryOutcomes measure: Fatigue assessed with the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue 7a Instrument, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Bateman Horne Center, status: RECRUITING, city: Salt Lake City, state: Utah, zip: 84102, country: United States, contacts name: Lucinda Bateman, MD, role: CONTACT, phone: 801-359-7400, email: lbateman@batemanhornecenter.org, contacts name: Suzanne D Vernon, PhD, role: CONTACT, phone: (801) 359-7400, email: sdvernon@batemanhornecenter.org, geoPoint lat: 40.76078, lon: -111.89105, hasResults: False
protocolSection identificationModule nctId: NCT06316830, orgStudyIdInfo id: STUDY00000075, briefTitle: Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose, acronym: Optimal Bup, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-06-30, completionDateStruct date: 2027-04-30, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Rhode Island Hospital, class: OTHER, collaborators name: Brown University, descriptionModule briefSummary: The investigators aim to test the effectiveness of a high maintenance daily dose of buprenorphine (24 mg) for improving outcomes among patients who used fentanyl compared to the standard daily dose (16 mg).The main question it aims to answer is: will patients who are randomly assigned to the high 24 mg maintenance dose, as compared to patients randomly assigned to the standard 16 mg maintenance dose, have improved retention in buprenorphine treatment (primary outcome), decreased use of non-prescribed opioids (secondary outcome), decreased opioid cravings (secondary outcome), and decreased risk of fatal and non-fatal opioid overdose (secondary outcome)., conditionsModule conditions: Opioid Use Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule interventions name: Buprenorphine, outcomesModule primaryOutcomes measure: Treatment Engagement, secondaryOutcomes measure: Use of non-prescribed opioids, secondaryOutcomes measure: Control of Opioid Cravings, secondaryOutcomes measure: Rate of Non-fatal or Fatal Opioid Overdose, secondaryOutcomes measure: Use of non-prescribed opioids, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False